Oddis Chester

Oddis Chester, a sole proprietorship based in Upper St. Clair, Pennsylvania, provides medical expert case review services to the Department of Health and Human Services Health Resources and Services Administration (HRSA) in support of the Vaccine Injury Compensation Program (VICP) and Countermeasures Injury Compensation Program (CICP), operating exclusively as a prime contractor under total small business set-asides. The vendor holds a single-award Blanket Purchase Agreement with HRSA worth $7.5 million with an ultimate completion date of May 14, 2031, and derives all 78 of its federal awards across fifteen years from that customer relationship.

Oddis Chester's capability portfolio is narrowly focused on medical review and expert analysis for vaccine injury claims. Representative work includes a $7,500 medical case review BPA call (awarded March 3, 2026) under the current five-year vehicle, a $5,625 medical expert services BPA call (awarded November 20, 2024), and a $15,000 expert analysis engagement for VICP case 18-1342 (awarded February 6, 2023). Individual task orders range from $600 to $18,200 in ceiling value and are issued on a firm fixed-price basis. The vendor conducts detailed medical record reviews, expert causation assessment, and supporting documentation preparation for HRSA's adjudication of claims filed under the no-fault vaccine injury program.

Customer concentration is absolute — 100% of awards and combined potential value flow from HRSA Headquarters. The vendor's primary revenue vehicle, Blanket Purchase Agreement HHSH250201400055B, anchors 37 task orders valued at $129 thousand in combined potential value; three additional legacy BPAs (75R60219A00092, 75R60221A00036, and HHSH250201100076B) account for the remaining 36 historical task orders. Recent activity has declined sharply — nine awards in 2021, six in 2022, two in 2023, one in 2024, and two in 2026 — reflecting the supplier's narrow niche within VICP case evaluation. Only one award (combined potential value $8 thousand) reaches ultimate completion inside the next twenty-four months, providing minimal recompete exposure in the near term. Combined potential value across all awards is $8.6 million, though combined dollars obligated across the entire footprint stand at only $270 thousand (3% of potential value), indicating substantial ceiling-to-invoiced variance and task-order pacing that does not consume the full contract capacity.